v3.26.1
Note 1 - Summary of Significant Accounting Policies 1 (Details Textual)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 01, 2012
USD ($)
Jun. 30, 2026
USD ($)
shares
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
shares
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Mar. 31, 2026
USD ($)
Dec. 31, 2024
USD ($)
Aug. 31, 2023
USD ($)
Oct. 31, 2016
USD ($)
Dec. 31, 2013
USD ($)
Debt Securities, Held-to-Maturity, Allowance for Credit Loss, Excluding Accrued Interest   $ 0   $ 0   $ 0          
Debt Securities, Held-to-Maturity, Accrued Interest, after Allowance for Credit Loss   59,111   59,111   117,949          
Accounts Receivable, Allowance for Credit Loss   0   0   0          
Accounts Receivable, after Allowance for Credit Loss   350,288 $ 396,155 350,288 $ 396,155 336,539   $ 486,772      
Accounts Receivable, after Allowance for Credit Loss, Noncurrent   95,673   95,673   95,673          
Unbilled Receivables, Current   45,757   45,757   45,757          
Inventory Write-down   213,758 214,719 269,566 214,719            
Equity Method Investments   69,560   69,560   69,560          
Equity Method Investment, Other-than-Temporary Impairment       0 0            
Gain (Loss), Foreign Currency Transaction, before Tax   (683,434) 1,285,261 (281,024) 1,159,493            
Royalty, Percent of Sales 3.00%                    
Minimum Guaranteed Royalties, Income per Year $ 50,000                    
Licensing Agreement, Maximum License Fee and Milestone Payments                     $ 7,000,000
Licensing Agreement, Recognized                   $ 6,000,000  
Contract with Customer, Liability   1,116,132 1,132,815 1,116,132 1,132,815 1,119,788   $ 1,158,052      
Contract with Customer, Liability, Noncurrent   $ 1,085,753   $ 1,085,753   1,085,753          
Option Indexed to Issuer's Equity, Indexed Shares (in shares) | shares   5,700,000   5,700,000              
Government Assistance, Nonoperating Income, Increase (Decrease)   $ 34,814 $ 248,373 $ 34,814 $ 658,546            
Bioscience Innovation Grant [Member]                      
Government Assistance, Award Amount                 $ 1,158,000    
The Dutch Research and Development Act Grant [Member]                      
Government Assistance, Award Amount             $ 34,814        
Liability Warrants [Member]                      
Class of Warrant or Right, Outstanding (in shares) | shares   2,100,568   2,100,568              
License Agreement [Member]                      
Contract with Customer, Liability   $ 373,333   $ 373,333   $ 373,333          
Customer Concentration Risk [Member] | Revenue Benchmark [Member]                      
Number of Customers       4 2            
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer One [Member]                      
Concentration Risk, Percentage       46.00% 53.00%            
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Two [Member]                      
Concentration Risk, Percentage       16.00% 32.00%            
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Three [Member]                      
Concentration Risk, Percentage       13.00%              
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Four [Member]                      
Concentration Risk, Percentage       10.00%              
Customer Concentration Risk [Member] | Accounts Receivable [Member]                      
Number of Customers       3   3          
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]                      
Concentration Risk, Percentage       61.00%   65.00%          
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Two [Member]                      
Concentration Risk, Percentage       18.00%   19.00%          
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Three [Member]                      
Concentration Risk, Percentage       13.00%   15.00%